159 related articles for article (PubMed ID: 22688370)
21. Cystic fibrosis papers of the year 2017.
Doull I
Paediatr Respir Rev; 2018 Jun; 27():2-5. PubMed ID: 29627168
[TBL] [Abstract][Full Text] [Related]
22. Cystic Fibrosis: A Novel Pharmacologic Approach to Cystic Fibrosis Transmembrane Regulator Modulation Therapy.
Virant-Young D; Thomas J; Woiderski S; Powers M; Carlier J; McCarty J; Kupchick T; Larder A
J Am Osteopath Assoc; 2015 Sep; 115(9):546-55. PubMed ID: 26322933
[TBL] [Abstract][Full Text] [Related]
23. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
Ong T; Ramsey BW
Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
[TBL] [Abstract][Full Text] [Related]
24. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
[TBL] [Abstract][Full Text] [Related]
25. Breathing easier with combinations.
Azvolinsky A
Nat Biotechnol; 2015 Nov; 33(11):1128-30. PubMed ID: 26544137
[No Abstract] [Full Text] [Related]
26. CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy.
Guerra L; D'Oria S; Favia M; Castellani S; Santostasi T; Polizzi AM; Mariggiò MA; Gallo C; Casavola V; Montemurro P; Leonetti G; Manca A; Conese M
Pediatr Pulmonol; 2017 Jul; 52(7):900-908. PubMed ID: 28445004
[TBL] [Abstract][Full Text] [Related]
27. First cystic fibrosis drug advances towards approval.
Sheridan C
Nat Biotechnol; 2011 Jun; 29(6):465-6. PubMed ID: 21654649
[No Abstract] [Full Text] [Related]
28. Cystic fibrosis--what are the prospects for a cure?
Kumar S; Tana A; Shankar A
Eur J Intern Med; 2014 Nov; 25(9):803-7. PubMed ID: 25447947
[TBL] [Abstract][Full Text] [Related]
29. Recent advances in cystic fibrosis.
Doull IJ
Arch Dis Child; 2001 Jul; 85(1):62-6. PubMed ID: 11420207
[TBL] [Abstract][Full Text] [Related]
30. Carrier screening for cystic fibrosis in the new era of medications that restore CFTR function.
Massie J; Castellani C; Grody WW
Lancet; 2014 Mar; 383(9920):923-5. PubMed ID: 23992917
[No Abstract] [Full Text] [Related]
31. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis.
Derichs N
Eur Respir Rev; 2013 Mar; 22(127):58-65. PubMed ID: 23457166
[TBL] [Abstract][Full Text] [Related]
32. Excitement mounts for first disease-modifying cystic fibrosis drugs.
Opar A
Nat Rev Drug Discov; 2011 Jul; 10(7):479-80. PubMed ID: 21720393
[No Abstract] [Full Text] [Related]
33. Comparison of Organoid Swelling and
Graeber SY; van Mourik P; Vonk AM; Kruisselbrink E; Hirtz S; van der Ent CK; Mall MA; Beekman JM
Am J Respir Crit Care Med; 2020 Dec; 202(11):1589-1592. PubMed ID: 32687398
[No Abstract] [Full Text] [Related]
34. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.
Ramsey BW; Davies J; McElvaney NG; Tullis E; Bell SC; Dřevínek P; Griese M; McKone EF; Wainwright CE; Konstan MW; Moss R; Ratjen F; Sermet-Gaudelus I; Rowe SM; Dong Q; Rodriguez S; Yen K; Ordoñez C; Elborn JS;
N Engl J Med; 2011 Nov; 365(18):1663-72. PubMed ID: 22047557
[TBL] [Abstract][Full Text] [Related]
35. Cystic fibrosis: bridging the treatment gap in early childhood.
Davies JC
Lancet Respir Med; 2013 Aug; 1(6):433-4. PubMed ID: 24429232
[No Abstract] [Full Text] [Related]
36. Modifying disease in cystic fibrosis: current and future therapies on the horizon.
Ong T; Ramsey BW
Curr Opin Pulm Med; 2013 Nov; 19(6):645-51. PubMed ID: 24048086
[TBL] [Abstract][Full Text] [Related]
37. Mutation-specific therapy in cystic fibrosis: the earlier, the better.
Tümmler B
Lancet Respir Med; 2013 Oct; 1(8):591-592. PubMed ID: 24461654
[No Abstract] [Full Text] [Related]
38. Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.
Kotha K; Clancy JP
Ther Adv Respir Dis; 2013 Oct; 7(5):288-96. PubMed ID: 24004658
[TBL] [Abstract][Full Text] [Related]
39. Ivacaftor-induced sweat chloride reductions correlate with increases in airway surface liquid pH in cystic fibrosis.
Abou Alaiwa MH; Launspach JL; Grogan B; Carter S; Zabner J; Stoltz DA; Singh PK; McKone EF; Welsh MJ
JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089726
[TBL] [Abstract][Full Text] [Related]
40. Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?
Schneider EK; Reyes-Ortega F; Li J; Velkov T
Clin Pharmacol Ther; 2017 Jan; 101(1):130-141. PubMed ID: 27804127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
